RxDoctor Payments Data

Tammy Fox, APRN

Family · Lancaster, SCNPI 1033690706

Payments from drug & device makers

$1,983in general payments, 2019–2025

Across 46 payments — averaging $43.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$1K
  • Akebia Therapeutics Inc$261
  • Ardelyx, Inc.$199
  • Bayer$120
  • AstraZeneca$98
  • Veloxis Pharmaceuticals, Inc.$96
  • plus $150 from 4 others

What the payments were for

  • Food & beverage$1,983100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,983 in reported general payments places this provider in the 75th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$19,356
Medicare patients
66
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl17$111,112
VelphoroSucroferric Oxyhydroxide25$47,491
Sevelamer Carbonate126$23,345
AuryxiaFerric Citrate23$17,985
EliquisApixaban27$14,836
RetacritEpoetin Alfa-Epbx17$13,292
Calcium Acetate83$6,759
Potassium Chloride83$1,494
Midodrine Hcl26$1,273
Lidocaine-PrilocaineLidocaine/Prilocaine44$1,107
Furosemide188$907
Gabapentin70$627
Torsemide31$612
Chlorthalidone39$599
Amlodipine Besylate115$494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$20$47,49125 claims
Akebia Therapeutics IncAuryxia$261$17,98523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,248 family providers in South Carolina.

Other family in Lancaster

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →